- 関
- raloxifene
UpToDate Contents
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
English Journal
- Estrogens antagonize RUNX2-mediated osteoblast-driven osteoclastogenesis through regulating RANKL membrane association.
- Martin A1, Xiong J2, Koromila T3, Ji JS4, Chang S5, Song YS6, Miller JL7, Han CY8, Kostenuik P9, Krum SA10, Chimge NO11, Gabet Y12, Frenkel B13.
- Bone.Bone.2015 Jun;75:96-104. doi: 10.1016/j.bone.2015.02.007. Epub 2015 Feb 17.
- In addition to its thoroughly investigated role in bone formation, the osteoblast master transcription factor RUNX2 also promotes osteoclastogenesis and bone resorption. Here we demonstrate that 17β-estradiol (E2), strongly inhibits RUNX2-mediated osteoblast-driven osteoclastogenesis in co-cultures
- PMID 25701138
- The Effect of Osteoporosis Treatments on Fatigue Properties of Cortical Bone Tissue.
- Brock GR1, Chen JT1, Ingraffea AR2, MacLeay J3, Pluhar GE4, Boskey AL5, van der Meulen MC6.
- Bone reports.Bone Rep.2015 Jun 1;2:8-13.
- Bisphosphonates are commonly prescribed for treatment of osteoporosis. Long-term use of bisphosphonates has been correlated to atypical femoral fractures (AFF). AFFs arise from fatigue damage to bone tissue that cannot be repaired due to pharmacologic treatments. Despite fatigue being the primary da
- PMID 25642445
- Targeted Screen for Human UDP-Glucuronosyltransferases Inhibitors and the Evaluation of Potential Drug-Drug Interactions with Zafirlukast.
- Oda S1, Fujiwara R1, Kutsuno Y1, Fukami T1, Itoh T1, Yokoi T1, Nakajima M2.
- Drug metabolism and disposition: the biological fate of chemicals.Drug Metab Dispos.2015 Jun;43(6):812-8. doi: 10.1124/dmd.114.062141. Epub 2015 Apr 1.
- Inhibition of drug metabolizing enzymes is a major mechanism in drug-drug interactions (DDIs). A number of cases of DDIs via inhibition of UDP-glucuronosyltranseferases (UGTs) have been reported, although the changes in pharmacokinetics are relatively small in comparison with drugs that are metaboli
- PMID 25834030
Japanese Journal
- 閉経後骨粗鬆症治療薬, 塩酸ラロキシフェン(エビスタ^【○!R】錠60mg)の薬理作用と臨床成績
- 小林 裕幸,浜谷 越郎
- 日本薬理学雑誌 : FOLIA PHARMACOLOGICA JAPONICA 125(1), 37-48, 2005-01-01
- 塩酸ラロキシフェン(エビスタ®)は,米国イーライリリー社によって発見,開発されたベンゾチオフェン骨格を有する選択的エストロゲン受容体モジュレーター(Selective Estrogen Receptor Modulator:SERM)である.塩酸ラロキシフェンはラットおよびサルの卵巣切除(OVX)モデルにおいて腰椎,大腿骨などの骨密度の低下を抑制し,また,腰椎,大腿骨などにおいて,OVXによって生 …
- NAID 10014385254
- Continuing outcomes relevant to Evista : breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene
Related Links
- Osteoporosis Medication, Invasive Breast Cancer Risk Reduction - EVISTA.com. Learn about an osteoporosis treatment option.
Related Pictures